Identification of protein kinase C domains involved in its translocation induced by propofol. 2023

Soshi Narasaki, and Soma Noguchi, and Tomoaki Urabe, and Kana Harada, and Izumi Hide, and Shigeru Tanaka, and Yuhki Yanase, and Taketoshi Kajimoto, and Kazue Uchida, and Yasuo M Tsutsumi, and Norio Sakai
Dept of Mol & Pharmacol Neurosci, Grad Sch of Biomed & Health Sci, Hiroshima Univ, Japan; Dept of Anesthesiology & Critical Care, Grad Sch of Biomed & Health Sci, Hiroshima Univ, Japan.

Propofol is widely used for general anesthesia and sedation; however, the mechanisms of its anesthetic and adverse effects are not fully understood. We have previously shown that propofol activates protein kinase C (PKC) and induces its translocation in a subtype-specific manner. The purpose of this study was to identify the PKC domains involved in propofol-induced PKC translocation. The regulatory domains of PKC consist of C1 and C2 domains, and the C1 domain is subdivided into the C1A and C1B subdomains. Mutant PKCα and PKCδ with each domain deleted were fused with green fluorescent protein (GFP) and expressed in HeLa cells. Propofol-induced PKC translocation was observed by time-lapse imaging using a fluorescence microscope. The results showed that persistent propofol-induced PKC translocation to the plasma membrane was abolished by the deletion of both C1 and C2 domains in PKCα and by the deletion of the C1B domain in PKCδ. Therefore, propofol-induced PKC translocation involves the C1 and C2 domains of PKCα and the C1B domain of PKCδ. We also found that treatment with calphostin C, a C1 domain inhibitor, abolished propofol-induced PKCδ translocation. In addition, calphostin C inhibited the propofol-induced phosphorylation of endothelial nitric oxide synthase (eNOS). These results suggest that it may be possible to modulate the exertion of propofol effects by regulating the PKC domains involved in propofol-induced PKC translocation.

UI MeSH Term Description Entries
D007527 Isoenzymes Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics. Alloenzyme,Allozyme,Isoenzyme,Isozyme,Isozymes,Alloenzymes,Allozymes
D011493 Protein Kinase C An serine-threonine protein kinase that requires the presence of physiological concentrations of CALCIUM and membrane PHOSPHOLIPIDS. The additional presence of DIACYLGLYCEROLS markedly increases its sensitivity to both calcium and phospholipids. The sensitivity of the enzyme can also be increased by PHORBOL ESTERS and it is believed that protein kinase C is the receptor protein of tumor-promoting phorbol esters. Calcium Phospholipid-Dependent Protein Kinase,Calcium-Activated Phospholipid-Dependent Kinase,PKC Serine-Threonine Kinase,Phospholipid-Sensitive Calcium-Dependent Protein Kinase,Protein Kinase M,Calcium Activated Phospholipid Dependent Kinase,Calcium Phospholipid Dependent Protein Kinase,PKC Serine Threonine Kinase,Phospholipid Sensitive Calcium Dependent Protein Kinase,Phospholipid-Dependent Kinase, Calcium-Activated,Serine-Threonine Kinase, PKC
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015742 Propofol An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS. Disoprofol,2,6-Bis(1-methylethyl)phenol,2,6-Diisopropylphenol,Aquafol,Diprivan,Disoprivan,Fresofol,ICI-35,868,ICI-35868,Ivofol,Propofol Abbott,Propofol Fresenius,Propofol MCT,Propofol Rovi,Propofol-Lipuro,Recofol,2,6 Diisopropylphenol,ICI 35,868,ICI 35868,ICI35,868,ICI35868
D051571 Protein Kinase C-alpha A cytoplasmic serine threonine kinase involved in regulating CELL DIFFERENTIATION and CELLULAR PROLIFERATION. Overexpression of this enzyme has been shown to promote PHOSPHORYLATION of BCL-2 PROTO-ONCOGENE PROTEINS and chemoresistance in human acute leukemia cells. PKC-alpha Serine-Threonine Kinase,Protein Kinase C alpha,Protein Kinase C(alpha),PKC alpha Serine Threonine Kinase,Serine-Threonine Kinase, PKC-alpha
D021381 Protein Transport The process of moving proteins from one cellular compartment (including extracellular) to another by various sorting and transport mechanisms such as gated transport, protein translocation, and vesicular transport. Cellular Protein Targeting,Gated Protein Transport,Protein Targeting, Cellular,Protein Translocation,Transmembrane Protein Transport,Vesicular Protein Transport,Protein Localization Processes, Cellular,Protein Sorting,Protein Trafficking,Protein Transport, Gated,Protein Transport, Transmembrane,Protein Transport, Vesicular,Traffickings, Protein

Related Publications

Soshi Narasaki, and Soma Noguchi, and Tomoaki Urabe, and Kana Harada, and Izumi Hide, and Shigeru Tanaka, and Yuhki Yanase, and Taketoshi Kajimoto, and Kazue Uchida, and Yasuo M Tsutsumi, and Norio Sakai
May 2010, British journal of anaesthesia,
Soshi Narasaki, and Soma Noguchi, and Tomoaki Urabe, and Kana Harada, and Izumi Hide, and Shigeru Tanaka, and Yuhki Yanase, and Taketoshi Kajimoto, and Kazue Uchida, and Yasuo M Tsutsumi, and Norio Sakai
August 1995, Biochemical pharmacology,
Soshi Narasaki, and Soma Noguchi, and Tomoaki Urabe, and Kana Harada, and Izumi Hide, and Shigeru Tanaka, and Yuhki Yanase, and Taketoshi Kajimoto, and Kazue Uchida, and Yasuo M Tsutsumi, and Norio Sakai
February 1994, Biochemistry,
Soshi Narasaki, and Soma Noguchi, and Tomoaki Urabe, and Kana Harada, and Izumi Hide, and Shigeru Tanaka, and Yuhki Yanase, and Taketoshi Kajimoto, and Kazue Uchida, and Yasuo M Tsutsumi, and Norio Sakai
June 1996, Biochemical and biophysical research communications,
Soshi Narasaki, and Soma Noguchi, and Tomoaki Urabe, and Kana Harada, and Izumi Hide, and Shigeru Tanaka, and Yuhki Yanase, and Taketoshi Kajimoto, and Kazue Uchida, and Yasuo M Tsutsumi, and Norio Sakai
August 1994, FEBS letters,
Soshi Narasaki, and Soma Noguchi, and Tomoaki Urabe, and Kana Harada, and Izumi Hide, and Shigeru Tanaka, and Yuhki Yanase, and Taketoshi Kajimoto, and Kazue Uchida, and Yasuo M Tsutsumi, and Norio Sakai
December 1990, Proceedings of the National Academy of Sciences of the United States of America,
Soshi Narasaki, and Soma Noguchi, and Tomoaki Urabe, and Kana Harada, and Izumi Hide, and Shigeru Tanaka, and Yuhki Yanase, and Taketoshi Kajimoto, and Kazue Uchida, and Yasuo M Tsutsumi, and Norio Sakai
September 1988, Clinical and experimental immunology,
Soshi Narasaki, and Soma Noguchi, and Tomoaki Urabe, and Kana Harada, and Izumi Hide, and Shigeru Tanaka, and Yuhki Yanase, and Taketoshi Kajimoto, and Kazue Uchida, and Yasuo M Tsutsumi, and Norio Sakai
August 1998, Biochemistry,
Soshi Narasaki, and Soma Noguchi, and Tomoaki Urabe, and Kana Harada, and Izumi Hide, and Shigeru Tanaka, and Yuhki Yanase, and Taketoshi Kajimoto, and Kazue Uchida, and Yasuo M Tsutsumi, and Norio Sakai
January 2003, Methods in molecular biology (Clifton, N.J.),
Soshi Narasaki, and Soma Noguchi, and Tomoaki Urabe, and Kana Harada, and Izumi Hide, and Shigeru Tanaka, and Yuhki Yanase, and Taketoshi Kajimoto, and Kazue Uchida, and Yasuo M Tsutsumi, and Norio Sakai
May 2002, Brain research bulletin,
Copied contents to your clipboard!